Vitamins in Prevention of Renal Scars in Pyelonephritis
Not Applicable
Completed
- Conditions
- Acute Pyelonephritis.Urinary tract infection, site not specified
- Registration Number
- IRCT201103256102N1
- Lead Sponsor
- Tehran University of Medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
positive urine culture, clinical findings, and 99mTC-DMSA criteria of APN
Exclusion criteria: presence of neurogenic bladder, systemic hypertension, obstructive uropathy, high grade vesico-ureteral reflux (Grade 4-5)
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Renal scar. Timepoint: at least 6 month apart. Method of measurement: Criteria of developing scar in 99mTC-DMSA.
- Secondary Outcome Measures
Name Time Method Intolerance to vitamins. Timepoint: daily. Method of measurement: daily clinical observation.;No response to antibiotic thepay. Timepoint: daily. Method of measurement: urine culture at the 3rd day, clinical observation for fever and general condition.;Acute renal failure. Timepoint: daily at the time of hospitalization. Method of measurement: urine output, serum creatinine, blood pressure measuement.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie renal scarring in acute pyelonephritis and how do vitamins E and A modulate these pathways?
How do the anti-inflammatory effects of vitamins E and A compare to standard-of-care treatments in preventing renal scarring in children with pyelonephritis?
Are there specific biomarkers that can predict which children with acute pyelonephritis will respond to vitamin E and A supplementation for scar prevention?
What are the potential adverse events associated with high-dose vitamin E and A administration in pediatric pyelonephritis patients and how are they managed?
How do combination therapies of vitamins E and A compare to other antioxidant approaches in mitigating renal damage from urinary tract infections?